SCHEDULE: Rosalind Advisors Discloses Fennec Stake

Rosalind Advisors Inc. and related entities have reported beneficial ownership of 9.6% of Fennec Pharmaceuticals Inc. common shares as of June 30, 2026.

Summary

• Rosalind Advisors Inc., along with Steven Salamon, Gilad Aharon, and Rosalind Master Fund L.P., have filed a Schedule 13G, indicating their beneficial ownership of Fennec Pharmaceuticals Inc. common shares.
• As of June 30, 2026, Rosalind Advisors Inc. holds a 9.6% stake, Rosalind Master Fund L.P. holds 9.2%, and Steven Salamon and Gilad Aharon each hold 9.4%.
• The total number of shares beneficially owned by Rosalind Advisors Inc. is 3,321,333.
• Steven Salamon and Gilad Aharon each have sole voting and dispositive power over 66,666 shares and shared power over 3,188,001 shares.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily indicating a significant but not controlling stake in Fennec Pharmaceuticals. The lack of explicit forward-looking statements or negative news tempers any strong positive sentiment.

Positives

• Significant beneficial ownership reported by Rosalind Advisors Inc. (9.6%) and related parties, indicating substantial investor interest.
• The reporting persons disclaim beneficial ownership for the purpose of changing or influencing control, suggesting a passive investment approach.
• The filing is an amendment to a previous filing, indicating ongoing monitoring and reporting of holdings.

Negatives

• The filing does not provide specific details on the acquisition cost or strategy behind the investment.
• No forward-looking statements or specific performance metrics are included in this Schedule 13G filing.

Risks

• Potential for increased market activity or volatility if the reporting persons decide to alter their stake.
• The concentration of ownership among a few related entities could be a factor in future corporate actions.

Future Outlook

This filing is a Schedule 13G, which primarily reports ownership stakes and does not contain forward-looking statements or financial guidance from the company itself. The future outlook for Fennec Pharmaceuticals would be found in their own SEC filings.

Management Comments

• Rosalind Advisors Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.
• Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF.
• Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. Fennec Pharmaceuticals operates in the pharmaceutical sector, which often sees active institutional investment and potential for strategic partnerships or acquisitions.

Stakeholder Impact

• Shareholders: May view the increased stake by a significant investor as a positive sign of confidence, but also note the potential for future market activity.
• Management: May need to engage with Rosalind Advisors Inc. regarding their investment strategy.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Continued monitoring of Fennec Pharmaceuticals' stock performance and corporate actions by Rosalind Advisors Inc. and related parties.
• Potential for further filings if ownership levels change significantly.

Key Dates

Keywords

Fennec Pharmaceuticals, Rosalind Advisors, Schedule 13G, Beneficial Ownership, Common Shares, Investment Advisor, Portfolio Manager